GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (FRA:HTD) » Definitions » Cyclically Adjusted FCF per Share

Corcept Therapeutics (FRA:HTD) Cyclically Adjusted FCF per Share : €0.95 (As of Mar. 2025)


View and export this data going back to 2004. Start your Free Trial

What is Corcept Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Corcept Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2025 was €0.039. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.95 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Corcept Therapeutics's average Cyclically Adjusted FCF Growth Rate was 23.30% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 33.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 61.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Corcept Therapeutics was 97.90% per year. The lowest was 15.10% per year. And the median was 33.20% per year.

As of today (2025-06-25), Corcept Therapeutics's current stock price is €65.60. Corcept Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was €0.95. Corcept Therapeutics's Cyclically Adjusted Price-to-FCF of today is 69.05.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Corcept Therapeutics was 411.00. The lowest was 26.51. And the median was 52.23.


Corcept Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Corcept Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corcept Therapeutics Cyclically Adjusted FCF per Share Chart

Corcept Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.20 0.38 0.58 0.74 1.04

Corcept Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 0.84 0.83 1.04 0.95

Competitive Comparison of Corcept Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Corcept Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corcept Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Corcept Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Corcept Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Corcept Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.039/134.9266*134.9266
=0.039

Current CPI (Mar. 2025) = 134.9266.

Corcept Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.001 100.684 -0.001
201509 0.007 100.392 0.009
201512 0.035 99.792 0.047
201603 0.027 100.470 0.036
201606 0.012 101.688 0.016
201609 0.068 101.861 0.090
201612 0.036 101.863 0.048
201703 0.073 102.862 0.096
201706 0.111 103.349 0.145
201709 0.072 104.136 0.093
201712 0.164 104.011 0.213
201803 0.218 105.290 0.279
201806 0.102 106.317 0.129
201809 0.302 106.507 0.383
201812 0.150 105.998 0.191
201903 0.167 107.251 0.210
201906 0.183 108.070 0.228
201909 0.284 108.329 0.354
201912 0.354 108.420 0.441
202003 0.246 108.902 0.305
202006 0.383 108.767 0.475
202009 0.203 109.815 0.249
202012 0.225 109.897 0.276
202103 0.164 111.754 0.198
202106 0.290 114.631 0.341
202109 0.330 115.734 0.385
202112 0.357 117.630 0.409
202203 0.278 121.301 0.309
202206 0.148 125.017 0.160
202209 0.288 125.227 0.310
202212 0.271 125.222 0.292
202303 0.210 127.348 0.222
202306 0.356 128.729 0.373
202309 0.446 129.860 0.463
202312 0.049 129.419 0.051
202403 0.199 131.776 0.204
202406 0.344 132.554 0.350
202409 0.585 133.029 0.593
202412 0.475 133.157 0.481
202503 0.039 134.927 0.039

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Corcept Therapeutics  (FRA:HTD) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Corcept Therapeutics's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=65.60/0.95
=69.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Corcept Therapeutics was 411.00. The lowest was 26.51. And the median was 52.23.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Corcept Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Corcept Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

Corcept Therapeutics Headlines

From GuruFocus